Ask AI
RRMM Decision Tool
Optimizing Therapy in Relapsed/Refractory Multiple Myeloma

Released: August 07, 2026

About This Tool & Disclaimer

Decera Clinical Education is grateful to Natalie S. Callander, MD; Sarah A. Holstein, MD, PhD; Carol Ann Huff, MD; Shaji Kumar, MD; Sagar Lonial, MD, FACP, FASCO, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in July 2026 and reflects the expert opinions and guidelines available at that time.

The goal of the tool is to educate clinicians on making optimal management choices for treating patients with relapsed/refractory multiple myeloma.

A series of questions allows the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include previous treatment history and refractoriness to these therapies, cytogenetic risk profile, and fitness.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with multiple myeloma. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate for making management decisions.

This tool assumes a “standard” patient with multiple myeloma with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display expert recommendations for that specific patient case.

For additional information on best practices in the management of patients with multiple myeloma, please see our online educational program titled, “Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support” with contributions from numerous additional expert faculty, including Muhamed Baljevic, MD, FACP; Alfred Garfall, MD; Charise Gleason, MSN, NP-C, AOCNP; and Jonathan Ticku, MD.

This program is supported by an educational grant from Pfizer Inc.

©2026 Decera Clinical Education. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Recommendations on Treatment for Relapsed/Refractory Multiple Myeloma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for patients with relapsed/refractory multiple myeloma. The information provided is based on expert guidance from Natalie S. Callander, MD; Sarah A. Holstein, MD, PhD; Carol Ann Huff, MD; Shaji Kumar, MD; Sagar Lonial, MD, FACP, FASCO.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of the material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Recommendations on Treatment for Relapsed/Refractory Multiple Myeloma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content